抄録
Cancer chemotherapy outcomes have improved markedly after the introduction of cytotoxic anticancer drugs, molecular target medicines, and immune checkpoint inhibitors (ICIs) into clinical practice. Chemotherapy regimens are specified treatment plans that include the dose of each anticancer drug, duration of treatment, and other supportive care drugs such as antiemetics. A chemotherapy regimen leads to the standardization of cancer pharmacotherapy, leading to medical safety and efficiency. Most molecular target medicines and ICIs have companion diagnostic agents (CDxs) that predict the treatment effect based on the gene variant (driver gene) and its expression level. In addition, oncogene panel tests have recently become covered by health insurance in Japan. However, there are some strict regulations and problems with their clinical use. Most molecular target medicines and ICIs have various side effects that are different from those of cytotoxic anticancer drugs. To provide more effective care and nursing to patients receiving cancer chemotherapy, clinical nurses need to understand the basic pharmacologic characteristics of each cancer medicine and provide patients with information about side effects and potential effects on daily life.
| 本文言語 | 英語 |
|---|---|
| ページ(範囲) | 416-420 |
| ページ数 | 5 |
| ジャーナル | Folia Pharmacologica Japonica |
| 巻 | 157 |
| 号 | 6 |
| DOI | |
| 出版ステータス | 出版済み - 2022 |
| 外部発表 | はい |
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
-
SDG 3 すべての人に健康と福祉を
All Science Journal Classification (ASJC) codes
- 薬理学
フィンガープリント
「Promotion of multidisciplinary collaboration in cancer chemotherapy — basic knowledge of medicines for clinical nurses」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。引用スタイル
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver